Physicians' Academy for Cardiovascular Education
Member

SGLT-2 inhibitor did not decrease risk of stroke in diabetic patients

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

Zinman B, Inzucchi SE, Lachin, ScD JM, et al. - Stroke. 2017;48: published online ahead of print

Background

Diabetes mellitus (DM) patients have a 2-fold increased risk of stroke compared with individuals without DM [1]. With the exception of pioglitazone and semaglutide, intensive or specific glucose-lowering agents have not significantly reduced the risk of stroke in type 2 DM (T2DM) patients [2-5].

In this analysis of 7020 patients enrolled in the EMPA-REG OUTCOME trial, the impact of empagliflozin versus placebo on cerebrovascular events was evaluated.

Main results

Conclusion

In T2DM patients at high cardiovascular risk enrolled in the EMPA-REG OUTCOME trial, empagliflozin, when compared with placebo, was not associated with either a reduction or an increase in the risk of cerebrovascular events.

References

Show references

Find this article online at Stroke